BioSpace News Archive

Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801.

EmbedTek, LLC, a technology (IoT) company specializing in the design and manufacture of embedded computer systems, software, sensors, and integrated displays, announced today that it has begun production and is accepting orders for PariRange™, a peer-to-peer social distancing and contact tracing device.

Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced the successful completion of the refinancing of its capital structure

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing.

Owens & Minor, Inc. announced the final results and expiration of its previously announced offers to purchase for cash up to a maximum aggregate purchase price, excluding accrued interest, equal to $240 million of the Company’s 3.875% senior notes due 2021 and 4.375% senior notes due 2024 and related consent solicitation, upon the terms and conditions described in the Company’s Offer to Purchase and Consent Solicitation Statement dated June 5, 2020.

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it and certain selling shareholders have commenced an underwritten public offering of 3,500,000 common shares of the Company,

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced the pricing of an upsized underwritten public offering of 2,649,600 shares of its common stock at a public offering price of $27.50 per share.

Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $142.00 per ADS.

Scientists at Cold Spring Harbor Laboratory (CSHL) have found that they can stop the growth of pancreatic cancer cells by interfering with the way the cells store cholesterol.

Plakous Therapeutics, Inc. received a notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant providing up to $1,725,000 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health (NIH). The grant will assist Plakous’ developme